Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Pancreatic Neoplasms 2Digestive System Neoplasms 2Pancreatic cancer, adult 1Pancreatic Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Endocrine Gland Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

trametinib 1ozanimod 1napabucasin 1guadecitabine 1ficlatuzumab 1Sorafenib 1Paclitaxel 1Nivolumab 1Leucovorin 1Irinotecan 1IDRX-42 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1Albumin-Bound Paclitaxel 15-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Digestive System Diseases × napabucasin × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡